Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing BT-1 and BT-2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

Inclusion criteria

• Patients with type II diabetes mellitus aged 19 years or older
• Patients with fasting plasma glucose≤270mg/dL at the screening visit
• Patients with 18.5kg/m^2≤BMI≤40kg/m^2 at the screening visit
• Patients who have signed an informed consent themselves after receiving detailed explanation about the clinical study

Exclusion criteria

• Patients with type 1 diabetes, secondary diabetes, gestational diabetes, diabetic coma or -pre-coma, metabolic acidosis including lactic acidosis and diabetic ketoacidosis
• Patients with a medical history of New York Heart Association(NYHA) class III~IV heart failure or with congestive heart failure, acute and unstable heart failure
• Patients with severe infectious disease or severe traumatic systemic disorders
• Patients with hypopituitarism or adrenal insufficiency, pulmonary infarction, severe pulmonary dysfunction and other hypoxemia
• Patients with galactose intolerance, lapp lactase deficiency, glucosegalactose malabsorption